Informations:
Erreur:
ID
19390
Description
Acetylcarnitine and Insulin Sensitivity; ODM derived from: https://clinicaltrials.gov/show/NCT00393770
Lien
https://clinicaltrials.gov/show/NCT00393770
Mots-clés
Versions (1)
- 28/12/2016 28/12/2016 -
Téléchargé le
28 décembre 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Type 2 Diabetes Mellitus NCT00393770
Eligibility Type 2 Diabetes Mellitus NCT00393770
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes Mellitus NCT00393770
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
criteria Three Minimum
Item
at least three of these
boolean
C0243161 (UMLS CUI [1,1])
C0205449 (UMLS CUI [1,2])
C1524031 (UMLS CUI [1,3])
C0205449 (UMLS CUI [1,2])
C1524031 (UMLS CUI [1,3])
Non-Insulin-Dependent Diabetes Mellitus Relative
Item
relatives with type 2 diabetes
boolean
C0011860 (UMLS CUI [1,1])
C0080103 (UMLS CUI [1,2])
C0080103 (UMLS CUI [1,2])
Age
Item
age between 40 and 65 years
boolean
C0001779 (UMLS CUI [1])
Systolic Pressure | Diastolic blood pressure
Item
systolic and diastolic pressure ≥ 140 or ≥90 mmhg respectively
boolean
C0871470 (UMLS CUI [1])
C0428883 (UMLS CUI [2])
C0428883 (UMLS CUI [2])
Body mass index | Gender
Item
body mass index ≥25 for men and ≥24 for women
boolean
C1305855 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
C0079399 (UMLS CUI [2])
Triglycerides
Item
triglycerides ≥200 mg/dl
boolean
C0041004 (UMLS CUI [1])
Creatinine measurement, serum | Proteinuria
Item
serum creatinine ≤1.5 mg/dl, proteinuria ≤ 0.5g/24h
boolean
C0201976 (UMLS CUI [1])
C0033687 (UMLS CUI [2])
C0033687 (UMLS CUI [2])
Comprehension Study Protocol
Item
capacity to understand the scope and the risks of the study
boolean
C0162340 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,2])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Steroids | Anti-Inflammatory Agents | Immunosuppressive Agents | Pharmaceutical Preparations Insulin Sensitivity | Pharmaceutical Preparations insulin secretion | Thiazolidinediones | Oral hypoglycemic
Item
concomitant treatment with steroids, anti-inflammatory and immunosuppressive drug, and any other drug acting on insulin sensitivity and/or insulin secretion, particularly glitazones and other oral hypoglycemic drug
boolean
C0038317 (UMLS CUI [1])
C0003209 (UMLS CUI [2])
C0021081 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C0920563 (UMLS CUI [4,2])
C0013227 (UMLS CUI [5,1])
C1256369 (UMLS CUI [5,2])
C1257987 (UMLS CUI [6])
C0359086 (UMLS CUI [7])
C0003209 (UMLS CUI [2])
C0021081 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C0920563 (UMLS CUI [4,2])
C0013227 (UMLS CUI [5,1])
C1256369 (UMLS CUI [5,2])
C1257987 (UMLS CUI [6])
C0359086 (UMLS CUI [7])
Acetylcarnitine
Item
treatment with l-acetylcarnitine in the six months before the study
boolean
C0001040 (UMLS CUI [1])
Metformin
Item
previous or concomitant treatment with metformin
boolean
C0025598 (UMLS CUI [1])
Comprehension Study Protocol Unable
Item
legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the trial.
boolean
C0162340 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
C2348563 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])